Abstract: Compounds of general formula (I): (Formula I)) wherein R1, Q, R3, R4, R5, R6, R7 and Ar1 are as defined herein are inhibitors of class I histone deacetylases and are of use in the treatment of lysosomal storage disorders, especially Niemann-Pick type C disease, as well as other lysosomal storage disorders, defective autophagy, accumulation of free cholesterol and mycobacterial diseases.

Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.

Abstract: The present disclosure relates to an immunogenic agent comprising Dna J heat shock protein family (Hsp40) member B7 or an immunogenic fragment thereof; a DNA vaccine comprising a nucleic acid encoding said protein or at least one immunogenic fragment thereof; a pharmaceutical composition or vector or DNA vaccine for use in the treatment of cancer; and a method of treating cancer comprising the use of said immunogenic agent or pharmaceutical composition or vector or DNA vaccine.

Abstract: Methods and apparatus for analysis of nano-objects using wide-field bright field transmission techniques are described. Such methods may comprise acquiring a plurality of images of a sample comprising a plurality of nano-objects using bright field illumination via a continuously variable spectral filter, and identifying a nano-object within the sample in the plurality of images, wherein the position of the nano-object changes between images. Using data extracted from the plurality of images, an extinction cross-section of the identified nano-object may be quantitatively determined.

Abstract: A method of producing at least one compound comprising an alkenyl group from at least one compound comprising an alkyl group having two or more carbon atoms, the method comprising: (i) Providing a mixture comprising carbon dioxide and at least one compound comprising an alkyl group having two or more carbon atoms; and (ii) Contacting said mixture with a catalyst comprising one or both of palladium and platinum and one or more lanthanide, thereby converting at least a portion of the at least one compound comprising an alkyl group having two or more carbon atoms into a compound comprising an alkenyl group, the total of the weight of the palladium and/or platinum being more than 0.1 wt % of the catalyst.

Abstract: This application relates to a water treatment process. The process comprises contacting contaminated water with a catalyst, introducing hydrogen and an oxygen-containing gas into the contaminated water, and reacting hydrogen and oxygen in the presence of the catalyst and the contaminated water.

Abstract: A method of direct oxidation of a hydrocarbon to produce an oxygenated reaction product, wherein said method comprises contacting a peroxide and oxygen and the hydrocarbon with a suspension of catalyst particles dispersed in a liquid reaction medium, wherein the catalyst particles are unsupported and comprise at least one transition metal.

Abstract: In an example, an avalanche photodiode comprises a substrate and a structure comprising a first layer and a second layer, the first and second layers over and parallel to the substrate, wherein the first layer is between the substrate and the second layer. The first layer is an Aluminium Arsenide Antimonide multiplication layer, and wherein the cross-sectional area parallel to the substrate of the first layer is smaller than that of the second layer, thereby forming a recess in a sidewall of the structure.

Abstract: The invention concerns a brace, ideally disposable, formed from a blank and, particularly but not exclusively, a neck or limb brace wherein the brace is contoured to fit about a wearer and comprises at least one, or a series of, crease line(s) that mirror(s) the contour of at least one edge of said brace and spaced from same by a selected amount whereby said edge can be folded or torn along at least one selected crease line to fit a wearer.

Abstract: The invention concerns a brace, ideally disposable, formed from a blank and, particularly but not exclusively, a neck or limb brace wherein the brace is contoured to fit about a wearer and comprises at least one, or a series of, crease line(s) that mirror(s) the contour of at least one edge of said brace and spaced from same by a selected amount whereby said edge can be folded or torn along at least one selected crease line to fit a wearer.

Abstract: The invention relates to a high throughput method for determining telomere length of mammalian chromosomal DNA; primers for use in said method; a kit comprising said primers; use of said method to diagnose or prognose or to determine the risk of developing a telomere shortening disease such as cancer, ageing, neurological disorders including Alzheimer's disease, Parkinson's disease and other dementias, brain infarction, heart disease, chronic HIV infection, chronic hepatitis, skin diseases, chronic inflammatory bowel disease including ulcerative colitis, anaemia, atherosclerosis, Barrett's oesophagus and cancers including pre-cancerous conditions, infertility, telomere syndromes including dyskeratosis congenita, aplastic anaemia, idiopathic pulmonary fibrosis, familial myelodysplastic syndrome-acute myeloid leukaemia, Hoyeraal-Hreiderasson syndrome, Revesz syndrome, Coats plus syndrome, bone marrow failure, and cryptogenic liver cirrhosis.

Abstract: Sepsis remains a leading cause of morbidity and mortality in neonates worldwide. There is also clinically a low threshold for suspicion of infection in neonates, in particular as presentation varies greatly from very subtle to catastrophic collapse. The lack of reliably sensitive tests and the potential life-threatening consequences of delayed treatment of infection results in the widespread use of empirical antibiotics exposing many infants without infection to broad-spectrum antibiotics. The present invention provides a series of patient-invariant biomarkers for screening neonates and other subjects for infection that predicts bacterial infection with high accuracy; and is further shown to have predictive value in identifying infection in suspected cases with blood-culture negative tests.

Abstract: A method for obtaining magnetic resonance imaging (MRI) echo-planar image (EPI) data, including providing a homogeneous, static background field; providing a gradient field to select a slice of an object for imaging; applying Radio-frequency (RF) pulses to excite magnetic resonance in the selected slice; and measuring a radio frequency signal emitted by the selected slice containing image data. The RF pulses are repeatedly applied separated by a time period shorter than a recovery time of static material in the selected slice such that the static material remains in a state of magnetic saturation, while dynamic material arriving within the slice since a previous RF pulse is not magnetically saturated.

Abstract: Microwave resonance cavities and associated methods and apparatus are described. In one example, a cavity (100) comprises a first and a second input port (102, 104) for inputting microwave radiation at a first and a second frequency respectively. The microwave radiation at the first frequency may be to excite a sample in the cavity whereas the microwave radiation at the second frequency may be to interrogate a sample in the cavity for analysis. The cavity has dimensions such that it resonates at both the first and the second frequency.

Abstract: The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterised by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.

Abstract: Methods and apparatus for analysis of nano-objects using wide-field bright field transmission techniques are described. Such methods may comprise acquiring a plurality of images of a sample (124) comprising a plurality of nano-objects using bright field illumination via a continuously variable spectral filter (114), and identifying a nano-object within the sample in the plurality of images, wherein the position of the nano-object changes between images. Using data extracted from the plurality of images, an extinction cross-section of the identified nano-object may be quantitatively determined.

Abstract: An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian cartilage damage using such progenitor cells or progeny.

Abstract: There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTMS, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no

Abstract: The present application concerns a method for identifying the nature of a bacterial infection from a peritoneal sample, in particular, whether it is a Gram-negative or Gram-positive infection, based upon the determination of one or more cellular and/or humoral markers in a sample.

Abstract: The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl3 and are useful for the treatment of cancer, particularly metastatic cancer.